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SMARCA2-deficiency confers 
sensitivity to targeted inhibition of 
SMARCA4 in esophageal squamous 
cell carcinoma cell lines
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Stefan Kornigg1, Stephan Zahn1, Wolfgang Sommergruber1, Norbert Schweifer1, 
Thomas Zichner  1, Andreas Schlattl1, Ralph A. Neumüller1, Junwei Shi  2, 
Christopher R. Vakoc3, Manfred Kögl1, Mark Petronczki1, Norbert Kraut1, Mark A. Pearson1 & 
Simon Wöhrle  1
SMARCA4/BRG1 and SMARCA2/BRM, the two mutually exclusive catalytic subunits of the BAF 
complex, display a well-established synthetic lethal relationship in SMARCA4-deficient cancers. 
Using CRISPR-Cas9 screening, we identify SMARCA4 as a novel dependency in SMARCA2-deficient 
esophageal squamous cell carcinoma (ESCC) models, reciprocal to the known synthetic lethal 
interaction. Restoration of SMARCA2 expression alleviates the dependency on SMARCA4, while 
engineered loss of SMARCA2 renders ESCC models vulnerable to concomitant depletion of SMARCA4. 
Dependency on SMARCA4 is linked to its ATPase activity, but not to bromodomain function. We 
highlight the relevance of SMARCA4 as a drug target in esophageal cancer using an engineered ESCC 
cell model harboring a SMARCA4 allele amenable to targeted proteolysis and identify SMARCA4-
dependent cell models with low or absent SMARCA2 expression from additional tumor types. 
These findings expand the concept of SMARCA2/SMARCA4 paralog dependency and suggest that 
pharmacological inhibition of SMARCA4 represents a novel therapeutic opportunity for SMARCA2-
deficient cancers.
Synthetic lethality is a well-established concept developed from genetic studies in fruit flies and yeast1–5 where 
concomitant deficiency of two (or more) synthetic lethal partner genes is lethal, while individual loss-of-function 
of any of the synthetic lethal partners is compatible with cell viability. Selective targeting of tumors harboring 
loss-of-function alterations of a synthetic lethal gene by pharmacological inhibition of the functional synthetic 
lethal partner has been proposed for cancer therapy. The response of patients with BRCA1/BRCA2-deficient 
tumors to Polymerase (PARP) inhibitors has demonstrated how this approach can be successfully exploited in the 
clinic6,7. Several other synthetic lethal interactions highlighting potential cancer drug targets have been described 
in pre-clinical models7–9. Most notably, synthetic lethal interactions of paralog genes, such as ENO1/ENO2 or 
STAG1/STAG210–12 with redundant - but cell essential - functions result in acute and strong dependencies on the 
functional paralog in tumor cells deficient for the corresponding paralog gene.
Cancer-relevant paralog dependencies are prominently observed for BRG1-Associated Factor (BAF) chro-
matin remodeling complexes13. BAF complexes, also referred to as Switch/Sucrose Non-Fermenting (SWI/SNF) 
complexes, are large, multi-subunit complexes that catalyze chromatin remodeling via ATP-dependent mobili-
zation of nucleosomes, thereby impacting on chromatin accessibility of the transcriptional machinery and global 
gene expression14. The core BAF complex consists of a DNA-dependent ATPase, as the sole known enzymatic 
activity, and three subunits (SMARCB1/BAF47/SNF5, SMARCC1/BAF155 and SMARCC2/BAF170) that are 
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critical for structural integrity and chromatin recruitment. BAF complexes are further variably composed of 
accessory components in a cell-type and context specific manner15. Multiple BAF components are represented by 
paralogous subunits that are incorporated into the complex in a mutual exclusive fashion. Most notably, the BAF 
ATPase function may be exerted by either SMARCA4 or its homologous paralog SMARCA216,17.
Loss-of-function alterations of individual BAF complex components, such as bi-allelic inactivation of the BAF 
core component SMARCB1 in malignant rhabdoid tumors18,19, are known oncogenic driver events, indicating a 
tumor suppressive role for BAF complexes20. Cancer-associated BAF alterations do not result in complete abroga-
tion of BAF activity, which would be detrimental for viability of most cells, implying that tumors are dependent 
on the aberrant function of the residual BAF complex13. This is exemplified by the ATPase subunit SMARCA4, 
which is frequently inactivated by loss-of-function mutations or epigenetic silencing in non-small cell lung can-
cer (NSCLC) and other tumor types21–24. Consequently, SMARCA4-deficient cell models are rendered highly 
dependent on the paralog ATPase SMARCA2 to maintain residual BAF activity25–27.
Esophageal carcinoma, which is histologically classified as adenocarcinoma or squamous cell carcinoma28, is 
one of the most common cancers worldwide with a five-year-survival rate ranging from 15 to 25%29. Esophageal 
squamous cell carcinoma (ESCC) is the predominant subtype of esophageal carcinoma, with particular high 
incidence in Eastern and Central Asia30,31. Treatment of ESCC is currently largely limited to surgery and chemo-
therapy/radiotherapy approaches32. With the exception of a few actionable genomic alterations, such as EGFR 
amplification, targeted therapy options for ESCC are limited33–36.
In this study, using a pooled single guide RNA (sgRNA) viability screen targeting epigenetic factors in a panel 
of ESCC cell models, we identify the BAF chromatin remodeling ATPase subunit SMARCA4 as a novel depend-
ency in a subset of ESCC cell lines with low or absent expression of SMARCA2. By applying SMARCA2 recon-
stitution and knock-out strategies in ESCC cell models, we define a novel synthetic lethal relationship reciprocal 
to the SMARCA2 dependency observed in SMARCA4-deficient cancer cells. This concept is further extended 
to non-ESCC cancer cell models, indicating SMARCA4 as a potential therapeutic target in tumors with low or 
absent expression of SMARCA2.
Results
CRISPR-Cas9 screening identifies SMARCA4 as a novel dependency in ESCC. To identify poten-
tial novel drug targets in ESCC, we applied domain-directed CRISPR-Cas9 screens37 across ten ESCC cell lines. 
Stable Cas9-expressing cell lines were transduced with a sgRNA library consisting of >1300 sgRNAs targeting 
179 epigenetic regulators38 and negative selection of sgRNA-expressing cells was monitored by next-generation 
sequencing after 18 population doublings (Fig. 1A). From these screens, we identified SMARCA4 as a strong 
dependency in a subset of the ESCC cell lines (Fig. 1B, Supplementary Dataset File 2 and 3). Six ESCC models 
(KYSE-270, T.T, KYSE-30, KYSE-410, KSYE-510 and COLO-680N) displayed relative Robust Rank Aggregation 
(α-RRA) scores below −0.5 similar to the known essential genes CDK1, POLR2A and RPA3. In contrast, four cell 
lines (KYSE-150, KYSE-70, KYSE-140 and KYSE-450) showed no or less dependency (α-RRA scores ≥ −0.5) 
on SMARCA4. Of note, none of the ESCC lines showed dependency on the paralogous BAF subunit SMARCA2 
(Fig. 1B).
Reciprocal to the known dependency of SMARCA4-deficient cancer cell lines on SMARCA225–27, the majority 
of SMARCA4-dependent ESCC cell lines (KYSE-270, KYSE-30, KSYE-510 and COLO-680N) displayed low or 
non-detectable levels of SMARCA2 mRNA and protein expression (Supplementary Fig. S1A). In contrast, T.T 
and KYSE-410 cells were dependent on SMARCA4 despite readily detectable SMARCA2 expression. SMARCA4 
mRNA and protein expression was detected in all ESCC lines (Supplementary Fig. S1A).
To establish a link between SMARCA2 expression levels and dependency on SMARCA4 beyond the cell mod-
els used in this study, we analyzed functional genomic datasets from recent pooled shRNA and CRISPR-Cas9 
viability screens39,40, including 14 and 16 ESCC cell lines, respectively. In both datasets, sensitivity to SMARCA4 
loss-of-function was anti-correlated with SMARCA2 expression levels (Supplementary Fig. S1B).
We performed depletion studies using individual sgRNAs to corroborate and strengthen the findings of the 
pooled CRISPR-Cas9 screens (Supplementary Fig. S2A). A higher frequency of loss-of-function mutations are 
observed with sgRNAs directed to sequences encoding functionally relevant protein domains37. Therefore, 17 
different sgRNAs targeting DEXDc-, helicaseC-, bromodomain or N-terminal coding regions of SMARCA4 
were tested in the KYSE-30 and KYSE-510 cell lines (Supplementary Fig. S2B). Both cell lines showed strong 
depletion effects with sgRNAs targeting the ATPase encoding regions, while efficacious depletion with 
bromodomain-directed sgRNAs was observed in KYSE-30 cells only. In contrast, N-terminal targeting sgRNAs 
displayed only mild effects in both models (Supplementary Fig. S2B).
We then screened a selected panel of SMARCA2-proficient and -deficient ESCC lines in a time-resolved 
fashion using the three most efficacious DEXDc- and bromodomain targeting sgRNAs (Fig. 2A). Absence 
of SMARCA2 protein expression in KYSE-270, KYSE-30, KYSE-510 and COLO-680N cells was confirmed 
by capillary Western immunoassay (Fig. 2B). No strong depletion effects were observed upon knock-out of 
SMARCA4 in the SMARCA2-proficient cell models KYSE-450, KYSE-140, KYSE-70 and KYSE-150 over a 
course of 28 days. In contrast, targeting SMARCA4 in the SMARCA2-deficient cell models KYSE-270, KYSE-
30, KYSE-510 and COLO-680N resulted in depletion effects similar or stronger than observed for the POLR2A 
positive control sgRNA (Fig. 2A). With the exception of KYSE-30, DEXDc-targeted sgRNAs showed stronger 
and faster depletion than bromodomain-directed sgRNAs in SMARCA2-deficient cells (Fig. 2A,B), indicating 
a requirement of SMARCA4 ATPase activity in the context of SMARCA4 dependence37. Of note, SMARCA4 
bromodomain-targeting, but not ATPase-directed, sgRNAs were included in the pooled sgRNA library. The effect 
observed with SMARCA4 bromodomain-targeting sgRNAs in the individual sgRNA depletion studies (Fig. 2) 
thus might be exacerbated in the pooled negative selection setting (Fig. 1B).
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These results highlight the BAF subunit SMARCA4 as a novel vulnerability in ESCC characterized by low or 
absent expression of its homologous ATPase SMARCA2.
SMARCA4 dependency is linked to its ATPase function. The requirement of SMARCA4 ATPase 
and bromodomain function in SMARCA2-deficient ESCC cells was further assessed by generating siRNA/
sgRNA-resistant SMARCA4 (SMARCA4res) expression constructs harboring loss-of-function mutations within 
the DEXDc- (K785A) and bromodomains (N1540A)41,42 (Fig. 3A). Wild-type and mutant forms of SMARCA4res 
were stably transduced in KYSE-510 cells and SMARCA4res expression was monitored by capillary Western 
immunoassay. Knock-down of SMARCA4 by siRNA led to depletion of SMARCA4 in parental KYSE-510 cells, 
but not in KYSE-510 cells expressing SMARCA4res variants (Fig. 3B). In line with previous results (Fig. 2A and 
Supplementary Fig. S2B), SMARCA4 sgRNAs were strongly depleted in empty vector control-transduced KYSE-
510. In contrast, wild-type SMARCA4res-expressing KYSE-510 cells were largely rendered inert to loss of endog-
enous SMARCA4. While ectopic expression of bromodomain-mutant (N1540A) SMARCA4res also protected 
KYSE-510 cells from SMARCA4 knock-out, the ATP-binding deficient form (K785A) of SMARCA4res did not 
rescue the depletion of SMARCA4 sgRNA-expressing KYSE-510 cells (Fig. 3C).
Wild-type and mutant forms of SMARCA4res were also stably expressed in the SMARCA2-deficient cell line 
KYSE-30 (Supplementary Fig. S3A). Similar to KYSE-510 cells, we found that ectopic expression of wild-type or 
bromodomain-mutant SMARCA4res, but not the ATP-binding deficient variant, rescued cells from loss of endog-
enous SMARCA4 (Supplementary Fig. S3B).
These studies suggest that the dependence of SMARCA2-deficient ESCC cell lines on SMARCA4 is related to 
SMARCA4 ATP-binding activity.
SMARCA2 displays an acute and strong synthetic lethal interaction with SMARCA4. To inter-
rogate the synthetic lethal interaction of SMARCA2 and SMARCA4 in ESCC, we ectopically expressed wild-type, 
DEXDc- (K755A) and bromodomain-mutant (N1482A) forms of SMARCA2 (SMARCA2ect) in KYSE-510 cells 
lacking endogenous SMARCA2 expression (Fig. 4A). Introduction of wild-type SMARCA2ect reversed the strong 
depletion effect of SMARCA4 sgRNAs observed in empty vector control-transduced KYSE-510 cells (Figs 3C and 
4A). In agreement with the dependence of KYSE-510 cells on SMARCA4 ATPase, but not bromodomain function 
(Fig. 3C), bromodomain-mutant SMARCA2ect, but not the ATP-binding deficient variant rendered KYSE-510 
cells inert to loss of SMARCA4 (Fig. 4A).
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Figure 1. SMARCA4 is a dependency in a subset of ESCC cell models. (A) Scheme of CRISPR-Cas9 depletion 
screens. Library plasmids were amplified and lentivirally packaged. The vectors encode for the respective 
sgRNA and GFP. Stably Cas9 expressing cells were transduced with the pooled library (using a multiplicity of 
infection of approximately 0.3) and cultured for 18 population doublings. sgRNA read counts from the genomic 
DNA obtained at the end of the screen were determined by next-generation sequencing (NGS) and compared 
to read counts derived from the DNA plasmid library. Sequences of sgRNAs from the library are listed in 
Supplementary Dataset File 1. (B) Heatmap of epigenome-wide CRISPR-Cas9 depletion screens in ten ESCC 
cell lines. Data shown are α-RRA scores (robust ranking aggregation) from pooled sgRNA depletion screens 
relative to mean of the α-RRA scores of three essential genes (CDK1, POLR2A, RPA3). The mean of the positive 
controls was set to −1. Cell lines are ranked by SMARCA4 α-RRA scores. α-RRA scores for all genes included 
in the screen and raw depletion values (provided as log2 fold-change values) for single gRNAs are listed in 
Supplementary Tables 3 and 4.
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To assess whether acute loss of SMARCA2 renders ESCC cell lines vulnerable to SMARCA4 depletion, we 
generated SMARCA2-null KYSE-450 monoclonal lines using CRISPR-Cas9 mediated gene knock-out (Fig. 4B). 
No depletion of SMARCA4 sgRNAs was observed in unedited, SMARCA2-proficient KYSE-450 monoclo-
nal lines (Fig. 4B), in line with previous results (Fig. 2A). In contrast, in two individual KYSE-450 SMARCA2 
knock-out clones, depletion of SMARCA4-targeting sgRNAs was observed, albeit more modestly than observed 
for the positive control sgRNA POLR2A (Fig. 4B). We subsequently confirmed these findings with an additional 
ESCC model, KYSE-150 (Supplementary Fig. S4). Strong depletion of SMARCA4 sgRNAs was not observed in 
SMARCA2-proficient clones, however, similar to KYSE-450 cells, loss of SMARCA2 rendered KYSE-150 cells 
dependent on SMARCA4 (Supplementary Fig. S4).
We wanted to extend our studies beyond ESCC cell models. Therefore, we selected non-ESCC cell lines with low 
SMARCA2 mRNA expression43 and identified four cell lines - HCT 116, SK-CO-1 (both colorectal carcinoma), 
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Figure 2. Selective dependency of SMARCA2-deficient ESCC models on SMARCA4. (A) Time-resolved 
CRISPR-Cas9 depletion studies. Fold depletion of sgRNA- and GFP-co-expressing cells relative to day 3 (d3) 
post-transduction was assessed by flow cytometry analysis in SMARCA2-proficient (blue) and SMARCA2-
deficient (red) cell lines over 28 days. Three individual sgRNAs were directed against the DEAD-like helicase 
superfamily (DEXDc) domain and the bromodomain (BD), respectively. Non-targeting (Neg. Contr.) and cell 
essential gene (POLR2A) targeting sgRNAs were included as negative and positive controls. Data are represented 
as mean ± SD of three independent experiments. (B) Heatmap summary of studies shown in (A) normalized to 
depletion of POLR2A-directed sgRNAs at day 28 (d28) and capillary Western immunoassay for SMARCA2 and 
SMARCA4 of ESCC cell lines shown in (A). GAPDH expression was used to monitor equal loading.
5Scientific RepoRtS |         (2019) 9:11661  | https://doi.org/10.1038/s41598-019-48152-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
HuP-T4 (pancreas carcinoma) and OV-90 (ovarian carcinoma) - with low or non-detectable SMARCA2 protein 
expression suitable for CRISPR-Cas9 depletion studies (Supplementary Fig. S5). Similar to the effects observed in 
ESCC cell lines, strong depletion of SMARCA4 sgRNAs was observed in all four SMARCA2-deficient cell models 
tested.
In summary, the SMARCA2 reconstitution and knock-out studies demonstrate a strong and hard-wired 
synthetic lethal interaction of SMARCA2 and SMARCA4 in ESCC cell models. Further, our data highlight 
SMARCA4 as a universal vulnerability of SMARCA2-deficient cancer cells, irrespective of the tumor type.
Pharmacological targeting of SMARCA4 impairs viability of a SMARCA2-null ESCC model. A 
sgRNA-resistant SMARCA4 expression construct in which the SMARCA4 bromodomain is replaced with 
the bromodomain of BRD9 (SMARCA4res-BDBRD9) was designed to determine whether acute degradation of 
SMARCA4 represents a therapeutic approach against SMARCA2-deficient cancers (Fig. 5A). The bromodo-
main substitution renders the SMARCA4 variant susceptible to targeted degradation via a potent and highly 
selective Proteolysis Targeting Chimera (PROTAC) directed against the bromodomain of BRD9, referred 
to as dBRD944. SMARCA4res-BDBRD9 was transduced in SMARCA4-dependent KYSE-30 cells and, subse-
quently, a monoclonal line harboring knock-out of the endogenous form of SMARCA4 was generated (KYSE-
30-SMARCA4res-BDBRD9). Treatment with dBRD9 for four hours led to a decrease in SMARCA4 protein levels 
in the KYSE-30-SMARCA4res-BDBRD9 cell line, but not parental KYSE-30 cells (Fig. 5B). Ectopic expression 
of SMARCA4res-BDBRD9 rendered KYSE-30-SMARCA4res-BDBRD9 cells inert to SMARCA4-targeting sgR-
NAs, indicating functionality and sufficient expression of the bromodomain substituted SMARCA4 variant 
(Supplementary Fig. S6). In line with the genetic depletion of SMARCA4, dBRD9-mediated degradation of 
SMARCA4 was accompanied by decreased viability of KYSE-30-SMARCA4res-BDBRD9 cells with a half maximal 
inhibitory concentration (IC50) of 322 ± 122 nM. In contrast, parental KYSE-30 cells were not affected by treat-
ment with dBRD9 (Fig. 5C).
The results indicate that pharmacological targeting of SMARCA4 might constitute a novel therapeutic 
approach for the treatment of SMARCA2-deficient tumors.
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Figure 4. SMARCA2 and SMARCA4 display an acute synthetic lethal interaction in ESCC cells lines. 
(A) SMARCA2 reconstitution in SMARCA2-deficient KYSE-510 cells alleviates SMARCA4 dependency. 
Location of ATP-binding- and bromodomain (BD)-inactivating mutations in SMARCA2 (designated as 
SMARCA2ect) is indicated. DEXDc, DEAD-like helicases superfamily; BD, bromodomain. Time-resolved 
CRISPR-Cas9 depletion studies in SMARCA2ect expressing KYSE-510 cells. Fold depletion of sgRNA- and 
GFP-co-expressing cells relative to day 3 (d3) post-transduction was assessed by flow cytometry analysis over 
28 days (n = 1 experimental replicate). Expression of SMARCA2ect variants was determined using capillary 
Western immunoassay. GAPDH expression was used to monitor equal loading. (B) SMARCA2 inactivation 
elicits dependency on SMARCA4. Time-resolved CRISPR-Cas9 depletion studies in SMARCA2-proficient and 
-deficient (KO) KYSE-450 monoclonal cell lines. Fold depletion of sgRNA- and GFP-co-expressing cells relative 
to day 3 (d3) post-transduction was assessed by flow cytometry analysis over 28 days (n = 1 experimental 
replicate). Knock-out of SMARCA2 was confirmed using capillary Western immunoassay. GAPDH expression 
was used to monitor equal loading.
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Discussion
Besides surgery, chemotherapy and radiotherapy regimens constitute the mainstay of clinical therapy of ESCC. 
Responses to combination chemotherapy regimens are short-lived in advanced ESCC due to the rapid emergence 
of resistance45,46. While recent large scale genomic analyses have provided a detailed landscape of genomic alter-
ations in ESCC33–36, approaches to clinically exploit selective vulnerabilities in ESCC with targeted agents have 
proven unsuccessful to date45,47,48.
The results of this study uncover the BAF complex ATPase SMARCA4 as a novel vulnerability in a subset 
of ESCC cell lines characterized by low or absent expression of SMARCA2 - a relationship reciprocal to the 
known synthetic lethal interaction between SMARCA2 and SMARCA4 in SMARCA4-deficient cancer cell 
lines25–27. We demonstrate that lack of SMARCA2 is both required and sufficient to induce dependency on the 
paralogous ATPase SMARCA4. These findings extend the concept of synthetic lethality between SMARCA2 
and SMARCA4 in cancer cells. In addition to ESCC cell models, SMARCA2-deficient colorectal, pancreas and 
ovarian carcinoma cell lines display SMARCA4 dependency, indicating that the interdependence of SMARCA2 
and SMARCA4 is hard-wired and context-independent. SMARCA4 dependency of SMARCA2-deficient cell 
lines is linked to its ATPase, but not bromodomain, function. This result is in line with a strict requirement on 
SMARCA2 ATPase activity in SMARCA4-mutant NSCLC cell lines25,41. Either SMARCA2 or SMARCA4 are 
sufficient to rescue from loss of SMARCA2 ATPase activity, further emphasizing the context-independent nature 
of SMARCA2/ SMARCA4 synthetic lethality.
Of note, two ESCC cell lines, T.T and KYSE-410, display dependence on SMARCA4 despite readily detectable 
levels of SMARCA2. In various cellular contexts, SMARCA4 has been linked to an oncogenic function49 and high 
expression levels of SMARCA4 are associated with poor prognosis in multiple tumor types50. A critical require-
ment on SMARCA4 in promoting MYC-dependent transcription has been described in SMARCA2-proficient 
acute leukemia cell models51. Thus, the dependency on SMARCA4 in the presence of SMARCA2 in T.T and 
KYSE-410 cells might be attributed to a context-dependent requirement on SMARCA4 function distinct from 
the paralog interdependence. Further work is required to elucidate the mechanisms underlying the dependency 
on SMARCA4 in the SMARCA2-proficient ESCC cell models.
In contrast, the function of SMARCA4 in cancer has also been linked to a tumor suppressive role. Inactivating 
mutations of SMARCA4 are frequently observed in human cancer, most prominently in non-small cell lung 
cancer (NSCLC)13,22,52–55. The tumor suppressive function of SMARCA4 is corroborated by Smarca4 knock-out 
studies in mice. While homozygous deletion of Smarca4 is embryonic lethal, heterozygous loss of Smarca4 pre-
disposes to tumor formation of epithelial origin56,57. Lung-specific, conditional ablation of Smarca4 enhances 
tumor formation in a carcinogen-induced lung cancer model58. Tumor formation in Smarca4 heterozygous mice 
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Figure 5. Pharmacological targeting of SMARCA4 impairs proliferation of SMARCA2-deficient ESCC 
KYSE-30 cells. (A) Schematic representation of siRNA/sgRNA-resistant SMARCA4 variant with substituted 
BRD9 bromodomain (SMARCA4res-BDBRD9). KYSE-30 cells were stably transduced with SMARCA4res-
BDBRD9 followed by knock-out of endogenous SMARCA4 and generation of a monoclonal cell line (KYSE-30-
SMARCA4res-BDBRD9). (B) Capillary Western immunoassay for SMARCA4 in parental KYSE-30 and KYSE-
30-SMARCA4res-BDBRD9 upon dBRD9 treatment for 4 h with the indicated doses. GAPDH expression was used 
to monitor equal loading. Quantification of SMARCA4 expression (lower panel) is represented as mean ± SD 
of four independent experiments. (C) Cell viability assay. Parental KYSE-30 cells and KYSE-30-SMARCA4res-
BDBRD9 were treated as indicated with dBRD9 and cell viability was determined ten days post treatment. Data 
are represented as mean ± SD of four independent experiments.
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occurs with long latency and low penetrance56,57, indicating that for treatment of SMARCA4-dependent cancers 
a therapeutic index for transient inhibition of SMARCA4 might exist without the risk of secondary malignancies.
In contrast, loss-of-function mutations of SMARCA2 are primarily linked to developmental/neurological 
disorders59. Missense mutations or in-frame deletions affecting the ATPase function of SMARCA2 are causative 
for Nicolaides-Baraitser syndrome, a rare condition characterized by sparse hair, facial and limb abnormalities 
and intellectual disabilities60,61. In cancer, mutations of SMARCA2 are rarely observed14. The lack of SMARCA2 
expression in cancer cells might therefore be related to cell-specific and epigenetic regulation mechanisms50,62. 
A notable exception is adenoid cystic carcinoma (ACC), a rare type of cancer arising from salivary glands where 
mutations within the ATPase domain of SMARCA2 are found in approximately 5% of cases63, indicating a poten-
tial tumor suppressive function of SMARCA2 in this context.
Using a PROTAC approach in an engineered cell model, we demonstrate that pharmacological targeting of 
SMARCA4 effectively impairs proliferation of a SMARCA2-deficient cell line. Our data suggest that SMARCA4 
inhibition would allow for a selective, cancer-cell directed therapy sparing normal, SMARCA2-expressing cells 
and tissues. Expression of SMARCA2 is predominantly detected in brain, liver, muscle and endothelial cells 
and has been linked to slow-cycling and differentiated cell states64. While it is difficult to define a threshold for 
expression of SMARCA2 that maintains sufficient BAF functionality in the absence of SMARCA4, the fact that 
homozygous loss of SMARCA4 is embryonic lethal, indicates that SMARCA2 cannot universally compensate for 
SMARCA4 function56. In adult tissues, dual inactivation of SMARCA2 and SMARCA4 primarily affects viability 
of vascular endothelial cells65. Pharmacological targeting of SMARCA4 would therefore require a thorough anal-
ysis of potential toxicities in normal cell and tissues.
In human cancer also concomitant loss of SMARCA2 and SMARCA4 expression has been described25,66–68. In 
small-cell carcinomas of the ovary, hypercalcemic type (SCCOHTs), characterized by bi-allelic inactivating muta-
tions of SMARCA4, loss of SMARCA2 expression is frequently observed68–71. These examples depict a striking 
exemption of the concept of hard-wired SMARCA2/SMARCA4 paralog dependency and constitute a potential 
mechanism for resistance to BAF targeted cancer therapies72. Further studies are required to decipher whether 
alternative ATP-dependent nucleosome-remodeling complexes, such as ISWI and CHD complexes73, can fulfill a 
compensatory function in the absence of BAF activity.
Our study highlights the use of functional genomic screening for identification of novel vulnerabilities in 
cancer cell lines. Given the possibility to develop selective SMARCA4 ATPase inhibitors or PROTACs selectively 
inducing SMARCA4 proteolysis72,74,75 and tolerability of systemic SMARCA4 inactivation, the results of this study 
suggest that targeting of SMARCA4 might be a valuable strategy for the treatment of tumors characterized by low 
or absent expression of SMARCA2.
Methods
Cell culture and lentiviral transduction. KYSE-30 and KYSE-450 (ESCC) were cultured in 45% 
RPMI 1640 (Gibco) + 45% Ham’s F12 + 10% fetal calf serum (FCS). For cultivation of KYSE-70 and KYSE-410 
(ESCC) RPMI 1640 (Gibco) supplied with 10% FCS, whereas for KYSE-140, KYSE-150, KYSE-180, KYSE-510 
and COLO-680N (ESCC) RPMI1640 (ATCC #30-2001) + 10% FCS was used. T.T (ESCC) cell line was cul-
tured in DMEM:F12 (ATCC: 30-2006) containing 10% FCS. KYSE-270 (ESCC) was cultured in RPMI1640 
(Gibco) + HAM’s F12 (Gibco, 31765-027) (1:1) including 2 mM Glutamine and 2% FCS. HCT 116 (colon carci-
noma) cells were cultured in McCoy’s 5 A medium (Gibco, 36600-021) supplemented with GlutaMAX (Thermo, 
35050061) and 10% FCS, SK-CO-1 (colon carcinoma) was cultured in EMEM (SIGMA, M5650) with GlutaMAX 
and 10% FCS supplemented with Sodium-Pyruvate, and OV-90 (ovarian carcinoma) was cultured in a 1:1 mix-
ture of MCDB 105 medium (Sigma, M6395) with glutamine and HEPES (Thermo, 15630080) containing a final 
concentration of 1.5 g/l sodium bicarbonate and Medium 199 (Sigma, M4530) containing a final concentration of 
2.2 g/l sodium bicarbonate. HuP-T4 (pancreas carcinoma) was cultured in MEM + Earl´s Salt (Gibco, 21090-022, 
no glutamine) + 20% FCS and GlutaMAX.
Lentiviral particles were generated via usage of the Lenti-X Single Shot protocol (Clontech, Mountain View, 
CA, US). Low passage cell lines were transduced with lentiviral expression vector encoding Cas9 and puromy-
cin and selected over two weeks. Cas9 editing efficacy was monitored via depletion of sgRNAs targeting pos-
itive control genes (CDK1, POLR2A or RPA3). For Cas9-expressing cell lines the following concentrations of 
Puromycin were added to the standard medium: T.T, and KYSE-270: 4 µg/ml; KYSE-70, KYSE-140, HCT 116, 
and HuP-T4: 2 µg/ml; KYSE-450, KYSE-510, SK-CO-1, and OV-90: 1 µg/ml; COLO-680N: 0.5 µg/ml; KYSE-30, 
KYSE-150, and KYSE-410: 0.25 µg/ml. The medium for the cell lines expressing SMARCA4res, SMARCA2ect, 
or SMARCA4-BDBRD9 was supplied with 25 µg/ml Hygromycin B. All supplements were obtained from Gibco, 
FCS (SH30071.03) from GE Healthcare Life Sciences, Puromycin from Sigma (P9620), and Hygromycin B from 
Invitrogen (10687010). Sources and information for authentication of cell lines (STR fingerprinting at Eurofins 
Genomics, Germany) used in this study are attached in Supplementary Table 1. All cell lines were tested nega-
tively for mycoplasma contamination.
CRISPR-Cas9 epigenome sgRNA library screens. Cas9-expressing ESCC cell lines were transduced 
with the indicated sgRNA library (Supplementary Dataset File 1) at a multiplicity of infection of approximately 
0.3 and cultured for 18 population doublings. Genomic DNA was purified using QIAamp DNA MiniKit (50) 
(Qiagen, 51304) and amplicons around the sgRNA sequences were PCR amplified using the following primers: 
LRG_F2: TCTTGTGGAAAGGACGAAACACCG; LRG_R2: TCTACTATTCTTTCCCCTGCACTGT. The PCR 
product of 40 PCR reactions was pooled and purified using QIAquick PCR Purification Kit (250) (Qiagen, 28106) 
and 50 ng of amplicons were used for the library generation with the TruSeq Nano DNA Library Prep kit for 
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NeoPrep (Illumina). The sequencing was conducted on a HiSeq. 1500 (Illumina) in rapid mode with the paired 
end protocol for 50 cycles.
Bioinformatics analysis of CRISPR-Cas9 screens. Statistical analysis of depletion signals was per-
formed with the MAGeCK tool (V 0.5.6)76,77. First guide level counts were generated from sequencing data with 
the ‘mageck count’ function with parameter ‘-norm-method control’. The set of negative control guides was 
derived from genes that never show strong depletion signals in the AVANA data set40 and that overlap with genes 
in our library. Next the ‘mageck test’ function was run with parameters ‘-remove-zero none -gene-lfc-method 
median’ to derive gene-level α-RRA scores for each cell line. To improve the comparability between the cell lines, 
α-RRA scores were scaled by using three positive control genes (CDK1, POLR2A, RPA3) such that the mean of 
these control genes was −1 for all cell lines.
CRISPR singleton-gRNA depletion experiments. The sgRNAs were designed using a tool provided by 
Zhang et al. (http://crispr.mit.edu/) and cloned into GFP encoding vectors. Cas9-expressing cells were transduced 
and the fraction of GFP-positive cells was determined on day 3 post-transduction. Cells were split for 21-28 days. 
Fold changes of initially transduced cell populations were calculated from day 3 to the respective time points. For 
the heatmap representation, depletion of GFP-positive cell populations on day 28 was related to the fraction  of 
GFP-positive cells  of the POLR2A positive control on day 28.
Sequences. All sgRNA sequences used for depletion experiments and generation of knock-out cell lines are 
listed in Supplementary Dataset File 1.
Quantitative reverse transcription PCR (qRT-PCR). RNA was isolated using RNeasy Mini Kit 
(Qiagen, 74106) and reversly transcribed using SuperScript™ VILO™ kit (Thermo Scientific). For qPCR analy-
sis, QuantiTect® Multiplex PCR kit (Qiagen, Hilden, Germany) and StepOne Real-Time PCR Sytem™ (Applied 
Biosytems) was used. The respective primers were all ordered from Applied Biosystems, including house-keeping 
genes: 18 S rRNA (VIC®/MGB, 4319413E), ACTB (VIC®/MGB, 4326315E), GAPDH (VIC®/MGB, 4326317E) 
and primers for SMARCA2 (Hs01030858_m1 MGB/FAM) and SMARCA4 (Hs00231324 MGB/FAM). 
SMARCA2/4 expression was calculated from duplicates in relation to three different house-keeping genes listed 
above.
Capillary western immunoassay. Lysates were generated using MSD Tris Lysis Buffer (Mesoscale 
#R60TX-2) supplied with Protease & Phosphatase Inhibitor Cocktail (1:100, Thermo Scientific#815-968-0747). 
Capillary Western immunoassay (Separation module, SMW004-1) was conducted according to the manufactur-
er’s protocol. Dilutions of protein were prepared to obtain a final protein concentration of 0.4 µg/µl.
Antibodies. Antibodies used were anti-BRG1/SMARCA4 (Cell Signaling #49360, 1:20 dilution for capil-
lary Western immunoassay), anti-SMARCA2 (SIGMA #HPA029981, 1:20 dilution for capillary Western immu-
noassay) and anti-GAPDH (abcam #ab9485, 1:10000 dilution for capillary Western immunoassay). Respective 
antibodies were used in a multiplex assay together with anti-GAPDH for relative quantification of protein levels.
Correlation of SMARCA4 dependency and SMARCA2 expression. SMARCA2 gene expression val-
ues (TPM – transcripts per million) were obtained from https://ordino.caleydoapp.org/ 43. SMARCA4 sensitivity 
measurements were obtained from McDonald et al.39 (RSA scores) and Meyers et al.40 (Ceres scores). The visual-
izations and statistical tests were performed using R version 3.5.0 (R Core Team (2018) R: A language and envi-
ronment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria; available online at 
https://www.R-project.org/.), including the R package ggplot2 version 3.0.0 (H. Wickham (2016) ggplot2: Elegant 
Graphics for Data Analysis; https://doi.org/10.1007/978-3-319-24277-4).
cDNA transgene vectors. For expression of SMARCA4res and SMARCA2ect the following constructs 
were generated by gene synthesis (GenScript, China) based on the SMARCA4 cDNA sequence NCBI NM_ 
001128844.1 and SMARCA2 cDNA sequence NCBI NM_003070.5 and cloning into the parental pLVX vec-
tor (Clontech, Mountain View, CA, US): pLVX-empty-IRES-Hygro; pLVX-SMARCA4-wt-IRES-Hygro; 
pLVX-SMARCA4-ATP-binding def icient (K785A)-IRES-Hygro; pLVX-SMARCA4-BD-dead-
(N1540A)-IRES-Hygro; pLVX-SMARCA2-wt-IRES-Hygro; pLVX-SMARCA2-ATP-binding-deficient(
K755A)-IRES-Hygro; pLVX-SMARCA2-BD-dead(N1482A)-IRES-Hygro; pLVX-SMARCA4res-BDBRD
9-IRES-Hygro. ATP-binding deficient and BD-dead sites were selected similar to known inactivating mutations 
in SMARCA2/441,42. The sequence of SMARCA4res-BDBRD9 is shown in Supplementary Table 3. All constructs 
were codon optimized to render the transgenes resistant towards siRNAs and sgRNAs. For SMARCA4, DEXDc 
(DEAD-like helicases superfamily) and HELIC (helicaseC) domains were annotated according to UniProt entry 
P51532, bromodomain (BD) was annotated according to NCBI entry 6597 (cd05516). For SMARCA2, domains 
were annotated according to UniProt entry P51531, bromodomain (BD) was annotated according to NCBI entry 
6595 (cd05516).
siRNA transfection. For siRNA-mediated gene knock-down, cells were reversely transfected using 
Lipofectamine RNAiMAX reagent according to the manufacturer’s protocol (Invitrogen, Waltham, MA, US). 
The final concentration of the respective siRNAs was 25 nM. The siRNA duplexes were purchased from Thermo 
Scientific/ Dharmacon: Non-targeting pool (D-001810-10-20), SMARCA4_1 (J-010431-06), SMARCA4_2 
(J-010431-07).
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CRISPR-Cas9-mediated gene knock-out. All-in-one pSpCas9 BB-2A-GFP (PX458) vectors were 
ordered from Genscript, China with sgRNAs targeting the N-terminus of SMARCA2/4 as listed in Supplementary 
Table 2. Cells were transfected using Lipofectamine 3000 reagent (Thermo Fisher Scientific, L3000015) and 
GFP-positive cells were sorted after 48 h using flow cytometry (SH800S Cell Sorter,Sony Biotechnology) and 
diluted to obtain single cell clones. Knock-out was monitored using capillary Western immunoassay.
Cell viability assay. KYSE-30-SMARCA4res-BDBRD9 and parental KYSE-30 cells were cultured for approxi-
mately 18 passages post-thawing and plated at low densities (100 cells/well) in a 96-well plate. The next day, cells 
were treated with varying doses of dBRD944 as indicated. Viability was determined using CellTiter-Glo (Promega, 
Madison, WI, US). Ten days post-treatment, 100 μl CellTiter-Glo solution were added directly to the cell medium, 
mixed and incubated for 10 min prior to determination of the luminescence signal.
Data Availability
All data generated or analyzed during this study are included in this published article and its Supplementary 
Information files.
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